Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Market watchers are anticipating strong performance driven by the robust sales of Lilly's blockbuster drugs, particularly its insulin portfolio.